Efficacy of three candidate Rift Valley fever vaccines in sheep

Vaccine

Volumn 30, Issue 23, 2012, Pages 3423-3429

  Kortekaas, J ^a   Antonis, A F G ^a   Kant, J ^a   Vloet, R P M ^a   Vogel, A ^a   Oreshkova, N ^a   De Boer, S M ^a,b   Bosch, B J ^b   Moormann, R J M ^a  

^a WAGENINGEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Nonspreading; Replicon; Rift Valley fever virus; Sheep; Subunit; Vaccine; Vector vaccine

Indexed keywords

GLYCOPROTEIN GN; NEUTRALIZING ANTIBODY; NEWCASTLE DISEASE VACCINE; RIFT VALLEY FEVER VIRUS VACCINE; UNCLASSIFIED DRUG; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DRUG EFFICACY; DRUG FORMULATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEVER; MORTALITY; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RIFT VALLEY FEVER; SHEEP; TREATMENT RESPONSE; VACCINATION; VIREMIA; VIRUS ISOLATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEVER; RIFT VALLEY FEVER; RIFT VALLEY FEVER VIRUS; SHEEP; SURVIVAL ANALYSIS; VACCINES, ATTENUATED; VACCINES, SYNTHETIC; VIRAL VACCINES; VIREMIA;

EID: 84859823074     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.03.027     Document Type: Article

References (39)

1. Elliott R.M. The bunyaviridae 1996, Plenum Press, New York & London.
2. Gerrard S.R., Nichol S.T. Synthesis, proteolytic processing and complex formation of N-terminally nested precursor proteins of the Rift Valley fever virus glycoproteins. Virology 2007, 357(January (2)):124-133.
3. Won S., Ikegami T., Peters C.J., Makino S. NSm protein of Rift Valley fever virus suppresses virus-induced apoptosis. J Virol 2007, 81(December (24)):13335-13345.
4. Ikegami T., Narayanan K., Won S., Kamitani W., Peters C.J., Makino S. Rift Valley fever virus NSs protein promotes post-transcriptional downregulation of protein kinase PKR and inhibits eIF2alpha phosphorylation. PLoS Pathog 2009, 5(February (2)):e1000287.
5. Bouloy M., Janzen C., Vialat P., Khun H., Pavlovic J., Huerre M., et al. Genetic evidence for an interferon-antagonistic function of Rift Valley fever virus nonstructural protein NSs. J Virol 2001, 75(February (3)):1371-1377.
6. Billecocq A., Spiegel M., Vialat P., Kohl A., Weber F., Bouloy M., et al. NSs protein of Rift Valley fever virus blocks interferon production by inhibiting host gene transcription. J Virol 2004, 78(September (18)):9798-9806.
7. Muller R., Saluzzo J.F., Lopez N., Dreier T., Turell M., Smith J., et al. Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment. Am J Trop Med Hyg 1995, 53(October (4)):405-411.
8. Daubney R., Hudson J.R., Garnham P.C. Enzootic hepatitis or Rift Valley fever: an undescribed disease of sheep, cattle and man from East Africa. J Pathol Bacteriol 1931, 34:545-579.
9. Findlay G.M., Daubney R. The virus of Rift Valley fever or enzoötic hepatitis. Lancet 1931, ii:1350-1351.
10. Gear J., De Meillon B., Measroch V., Davis D.H., Harwin H. Rift Valley fever in South Africa. 2. The occurrence of human cases in the Orange Free State, the North-Western Cape Province, the Western and Southern Transvaal. B. Field and laboratory investigation. S Afr Med J 1951, 25(December (49)):908-912.
11. Joubert J.D., Ferguson A.L., Gear J. Rift Valley fever in South Africa: 2. The occurrence of human cases in the Orange Free State, the north-western Cape province, the western and southern Transvaal. A epidemiological and clinical findings. S Afr Med J 1951, 25(December (48)):890-891.
12. McIntosh B.M., Russell D., dos Santos I., Gear J.H. Rift Valley fever in humans in South Africa. S Afr Med J 1980, 58(November (20)):803-806.
13. Meegan J.M., Hoogstraal H., Moussa M.I. An epizootic of Rift Valley fever in Egypt in 1977. Vet Rec 1979, 105(August (6)):124-125.
14. Madani T.A., Al-Mazrou Y.Y., Al-Jeffri M.H., Mishkhas A.A., Al-Rabeah A.M., Turkistani A.M., et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and laboratory characteristics. Clin Infect Dis: Off Publ Infect Dis Soc Am 2003, 37(October (8)):1084-1092.
15. Abdo-Salem S., Gerbier G., Bonnet P., Al-Qadasi M., Tran A., Thiry E., et al. Descriptive and spatial epidemiology of Rift Valley fever outbreak in Yemen 2000-2001. Ann N Y Acad Sci 2006, 1081(October):240-242.
16. Linthicum K.J., Anyamba A., Tucker C.J., Kelley P.W., Myers M.F., Peters C.J. Climate and satellite indicators to forecast Rift Valley fever epidemics in Kenya. Science 1999, 285(July (5426)):397-400.
17. Moutailler S., Krida G., Schaffner F., Vazeille M., Failloux A.B. Potential vectors of Rift Valley fever virus in the Mediterranean region. Vector Borne Zoonotic Dis 2008, 8(December (6)):749-753.
18. Turell M.J., Dohm D.J., Mores C.N., Terracina L., Wallette D.L., Hribar L.J., et al. Potential for North American mosquitoes to transmit Rift Valley fever virus. J Am Mosq Control Assoc 2008, 24(December (4)):502-507.
19. Turell M.J., Wilson W.C., Bennett K.E. Potential for North American mosquitoes (Diptera: Culicidae) to transmit Rift Valley fever virus. J Med Entomol 2010, 47(September (5)):884-889.
20. Smithburn K.C. Rift Valley fever; the neurotropic adaptation of the virus and the experimental use of this modified virus as a vaccine. Br J Exp Pathol 1949, 30(February (1)):1-16.
21. Caplen H., Peters C.J., Bishop D.H. Mutagen-directed attenuation of Rift Valley fever virus as a method for vaccine development. J Gen Virol 1985, 66(October (Pt 10)):2271-2277.
22. Bird B.H., Albarino C.G., Nichol S.T. Rift Valley fever virus lacking NSm proteins retains high virulence in vivo and may provide a model of human delayed onset neurologic disease. Virology 2007, 362(May (1)):10-15.
23. Dungu B., Louw I., Lubisi A., Hunter P., von Teichman B.F., Bouloy M. Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep. Vaccine 2010, 28(June (29)):4581-4587.
24. von Teichman B., Engelbrecht A., Zulu G., Dungu B., Pardini A., Bouloy M. Safety and efficacy of Rift Valley fever Smithburn and Clone 13 vaccines in calves. Vaccine 2011, 29(August (34)):5771-5777.
25. Bird B.H., Maartens L.H., Campbell S., Erasmus B.J., Erickson B.R., Dodd K.A., et al. Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, non-teratogenic, and confers protection from viremia, pyrexia, and abortion following lethal challenge in adult and pregnant sheep. J Virol 2011, October.
26. Morrill J.C., Peters C.J. Mucosal immunization of rhesus macaques with Rift Valley Fever MP-12 vaccine. J Infect Dis 2011, 204(August (4)):617-625.
27. Morrill J.C., Peters C.J. Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent Rift Valley fever virus. J Infect Dis 2011, 204(July (2)):229-236.
28. Bouloy M., Flick R. Reverse genetics technology for Rift Valley fever virus: current and future applications for the development of therapeutics and vaccines. Antivir Res 2009, 84(November (2)):101-118.
29. Boshra H., Lorenzo G., Busquets N., Brun A. Rift Valley fever: recent insights into pathogenesis and prevention. J Virol 2011, 85(July (13)):6098-6105.
30. Ikegami T., Makino S. Rift Valley fever vaccines. Vaccine 2009, 27(November (Suppl. 4)):D69-D72.
31. Kortekaas J., Dekker A., de Boer S.M., Weerdmeester K., Vloet R.P., de Wit A.A., et al. Intramuscular inoculation of calves with an experimental Newcastle disease virus-based vector vaccine elicits neutralizing antibodies against Rift Valley fever virus. Vaccine 2010, 28(March (11)):2271-2276.
32. Kortekaas J., de Boer S.M., Kant J., Vloet R.P., Antonis A.F., Moormann R.J. Rift Valley fever virus immunity provided by a paramyxovirus vaccine vector. Vaccine 2010, 28(June (27)):4394-4401.
33. de Boer S.M., Kortekaas J., Antonis A.F., Kant J., van Oploo J.L., Rottier P.J., et al. Rift Valley fever virus subunit vaccines confer complete protection against a lethal virus challenge. Vaccine 2010, 28(March (11)):2330-2339.
34. Kortekaas J., Oreshkova N., Cobos-Jimenez V., Vloet R.P., Potgieter C.A., Moormann R.J. Creation of a nonspreading Rift Valley fever virus. J Virol 2011, 85(December (23)):12622-12630.
35. Barnard B.J. Rift Valley fever vaccine - antibody and immune response in cattle to a live and an inactivated vaccine. J S Afr Vet Assoc 1979, 50(September (3)):155-157.
36. Karber G. Betrag zur kollektiven Behandlung pharmakologischer Reihenversuche. Arch Exp Path Pharmak 1931, 162:480-483.
37. Spearman C. The method of right and wrong cases (constant stimuli) without Gauss's formulae. Br J Psychol 1908, 2:227-242.
38. Drosten C., Gottig S., Schilling S., Asper M., Panning M., Schmitz H., et al. Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. J Clin Microbiol 2002, 40(July (7)):2323-2330.
39. Easterday B.C. Rift Valley fever. Adv Vet Sci 1965, 10:65-127.